The thesis

Veracyte operates in the diagnostics space with genomic classifiers for cancer diagnosis. The company shows 15.5% YoY revenue growth and 72.09% gross margin. Despite a conviction score of 6/100 indicating a dormant status, analyst consensus is BUY. The high P/E ratio of 28.4x raises valuation concerns.

Why now

The current macro context of inflation fears and market volatility makes Veracyte's stable revenue growth and high margins more attractive. The company's strong financials could be a catalyst for revaluation.

What to watch

Revenue growth acceleration or deceleration will be key to confirming or denying the thesis. The company's ability to maintain high gross margins (currently 72.09%) will also be an important indicator.

Key risks

The high valuation (P/E 28.4x) poses a risk if revenue growth slows. Execution risk is also present as the company needs to continue delivering on its genomic classifier products to maintain growth.

Theme exposure